With CD34+CD38−CD26+ as the phenotype, CML-LSCs could be detected on flow cytometry in most of our patients with UMRD, which was consistent with the notion that the residual leukemia cells after TKI treatment are insensitive stem cells. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.